Antonio Martinez received his MD degree at Medical Scchool, Autonomous University of Barcelona and PhD degrees from the Medical School at the University of Barcelona. After his residency in Pathology at the Hospital Clínic, he conducted specialized formation in genomics and proteomics and a postdoctoral fellowship in molecular pathology at the National Cancer Institute, Bethesda, MD. He joined the Laboratory of Pathology at the Hospital Clinic, University of Barcelona, where he became Professor of Anatomic Pathology and Chief of Surgical Pathology Section and Head of the Department. He is currently Researcher R3A of the Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) of Barcelona. He is member of the Executive Committee of the Sapanish Society of Pathology and Director of the National External Quality Assessment (EQA) Program in Pathology and Molecular Pathology of the Spanish Society of Pathology.
Dr Martinez’s research is focused on the pathological characterization of lymphoid neoplasms and the molecular analysis of genetic mechanisms involved in the development and progression of these tumors and the translation of this knowledge into the clinical practice. Hi is specially active in Viral Oncogenesis and the role of viral replication and secretory transformation of Immunodeficiency Associated Lymphoproliferative Disorders (IA-LD) with uninterrupted funding from ISCIII since 2008. Dr Martinez was member of Leukemia Lymphoma Molecular Profiling Project (NCI) from 2005 and International Extranodal Lymphoma Group from 2004. Dr Martinez is Pathologist Reviewer for the GELA and GELTAMO, as well as central reviewer in several clinical assays. He has given conferences and courses in several European countries and Latin American countries He is editor of 1 books, author of 3 book chapters, director of 6 doctoral thesis and has published 105 scientific articles in indexed journals, having received 5.203 citations with an H index of 32 (February 2021). He is director of the Spanish EQA in Pathology and correspondant member of the Spanish Society in the International Quality Networkin Pathlogy (IQNPath). During the last years he is involved in promoting quality biomarker access to cancer patients in Spain and Europe.